Journal
LABORATORY INVESTIGATION
Volume 101, Issue 8, Pages 1048-1059Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/s41374-021-00613-6
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science [16K15603, 20K16228, 24590388, 15K10083, 20K07686]
- Fujita Health University
- Aichi Cancer Research Foundation
- 24th General Assembly of the Japanese Association of Medical Sciences
- Aichi Health Promotion Foundation
- Indonesian Directorate General of Higher Education (DIKTI) Scholarship
- Grants-in-Aid for Scientific Research [16K15603, 20K16228, 20K07686, 15K10083, 24590388] Funding Source: KAKEN
Ask authors/readers for more resources
Depletion of DSS1 and PCID2, components of the TREX-2 complex, increases chemosensitivity in breast carcinomas independent of BRCA2 mutations. Particularly, the low expression of DSS1 in normal breast tissues suggests that targeting DSS1 could be a promising approach for treating breast cancer.
Breast cancer, the most common malignancy among women, is closely associated with mutations in the tumor suppressor gene BRCA. DSS1, a component of the TRanscription-EXport-2 (TREX-2) complex involved in transcription and mRNA nuclear export, stabilizes BRCA2 expression. DSS1 is also related to poor prognosis in patients with breast cancer owing to the induction of chemoresistance. Recently, BRCA2 was shown to be associated with the TREX-2 component PCID2, which prevents DNA:RNA hybrid R-loop formation and transcription-coupled DNA damage. This study aimed to elucidate the involvement of these TREX-2 components and BRCA2 in the chemosensitivity of breast carcinomas. Our results showed that compared with that in normal breast tissues, DSS1 expression was upregulated in human breast carcinoma, whereas PCID2 expression was comparable between normal and malignant tissues. We then compared patient survival time among groups divided by high or low expressions of DSS1, BRCA2, and PCID2. Increased DSS1 expression was significantly correlated with poor prognosis in recurrence-free survival time, whereas no differences were detected in the high and low BRCA2 and PCID2 expression groups. We performed in vitro analyses, including propidium iodide nuclear staining, single-cell gel electrophoresis, and clonogenic survival assays, using breast carcinoma cell lines. The results confirmed that DSS1 depletion significantly increased chemosensitivity, whereas overexpression conferred chemoresistance to breast cancer cell lines; however, BRCA2 expression did not affect chemosensitivity. Similar to DSS1, PCID2 expression was also inversely correlated with chemosensitivity. These results strongly suggest that DSS1 and PCID2 depletion is closely associated with increased chemosensitivity via BRCA2-independent DNA damage. Together with the finding that DSS1 is not highly expressed in normal breast tissues, these results demonstrate that DSS1 depletion confers a druggable trait and may contribute to the development of novel chemotherapeutic strategies to treat DSS1-depleted breast carcinomas independent of BRCA2 mutations. Depletion of DSS1 and PCID2, components of the TREX-2 complex, increases chemosensitivity via BRCA2-independent DNA damage in breast carcinomas. Unlike PCID2, DSS1 is not highly expressed in normal breast tissues; therefore, DSS1 depletion confers a druggable trait, providing an approach for treating breast carcinomas independent of BRCA2 mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available